arrow
M

Michele Merli

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
H指数:33
被引数:4,646

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST-CLL Study

真实世界中慢性淋巴细胞白血病的治疗方案选择决定因素:FIRST-CLL研究

2026-09-300
OAAI
The use of Bruton-tyrosine kinase inhibitors in non-IgM lymphoplasmacytic lymphoma: a retrospective Italian study

布鲁顿酪氨酸激酶抑制剂在非IgM淋巴浆细胞样淋巴瘤中的应用:一项意大利回顾性研究

2026-09-250
PRE
Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study

边缘区淋巴瘤首次复发后的生存情况:国际观察性NF10研究的前瞻性数据

2026-09-060
OAAI
Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi

直接抗病毒药物在合并HCV感染的HIV相关非霍奇金淋巴瘤患者中的作用:意大利淋巴瘤基金会研究

2026-09-060
PRE
Clinical Presentation, Treatment, and Outcomes of 28 Patients With Castleman Disease: A Retrospective Analysis of an Italian Cohort

临床表现、治疗及28例Castleman病患者结局:一项意大利队列的回顾性分析

2025-12-010
OAAI
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study

奥德诺克单抗单药治疗复发/难治性滤泡性淋巴瘤的EML-2研究中的健康相关生活质量

2025-05-230
OAAI
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a Fondazione Italiana Linfomi Cohort Study

R-miniCOMP与R-miniCHOP在老年非适合型弥漫大B细胞淋巴瘤患者中的比较疗效:来自意大利淋巴瘤基金会队列研究的见解

2025-05-130
PRE
Anti CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the RFolSTOP multicentre Italian study ( mar , 10.1007/s00277-025-06295-0 , 2025)

针对COVID-19大流行挑战的滤泡性淋巴瘤抗CD20维持策略:来自意大利多中心RFolSTOP研究的结果 (mar, 10.1007/s00277-025-06295-0, 2025)

2025-04-220
OA
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study (vol 109, pg 2297, 2024)

苯达莫司汀和利妥昔单抗作为症状性脾 marginal zone 淋巴瘤的一线治疗:长期结局及早期不可测量微小残留病获得的影响——来自 BRISMA/IELSG36 期 II 研究的数据(vol 109, pg 2297, 2024)

2025-04-010
OA
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma (vol 35, pg 1039, 2024)

奥德诺克单抗(odronextamab)在复发或难治性滤泡性淋巴瘤患者中的安全性与有效性(卷35,页1039,2024)

2025-03-011
PRE
Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy

奥德诺克单抗与莫斯单特珠单抗和艾普科单特珠单抗治疗经两线或以上系统治疗后复发/难治性滤泡性淋巴瘤(R/R FL)的匹配调整间接比较(MAICs)

BLOOD
IF23.1
2024-11-050
PRE
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma

odronextamab在复发或难治性滤泡性淋巴瘤患者中的安全性和有效性

2024-11-015
OAAI
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
2024-06-013
OAAI
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
2024-03-140
OAAI
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
2024-02-220
OAAI
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
2023-08-015
OAAI
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naive advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi
2023-05-285
OA
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
2023-04-014
OAAI